Carcinogenesis Advance Access originally published online on January 27, 2007
Carcinogenesis 2007 28(5):899-912; doi:10.1093/carcin/bgm019
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy
Cell Division and Cancer Group, Centro Nacional de Investigaciones Oncológicas, Melchor Fernández Almagro 3, E-28029 Madrid, Spain
* To whom correspondence should be addressed. Tel: +34 91 2246900; Fax: +34 91 7328033; Email: malumbres{at}cnio.es
Tumor cell proliferation is frequently associated with genetic or epigenetic alterations in key regulators of the cell cycle. Most known oncogenes and tumor suppressors target entry into the cell cycle and control the G1/S transition. However, tumor-associated alterations in spindle formation or chromosome segregation are also frequent and may result in chromosomal instability. In fact, a few centrosomal or mitotic proteins such as aurora A, polo-like kinase 1 and PTTG1 (securin) have been reported to act as oncogenes. Some spindle checkpoint regulators such as the BUB kinases or MAD2 protect cells from aberrant chromosome segregation and may therefore function as suppressors of malignant transformation. However, few cancer-associated mutations in these or other mitotic regulators have been described thus far and many of these molecules do not fit into the classical definition of ‘oncogenes’ or ‘tumor suppressor genes’. In some cases, both over-expression and decreased expression of these genes result in mitotic arrest. Moreover, some mitotic regulators such as MAD2 are either up- or down-regulated depending on the tumor types and, in both cases, these alterations result in chromosomal imbalances and tumor development. Minor changes in protein levels that do not compromise cell viability might therefore be sufficient to dysregulate the mitotic cycle and induce genomic instability. Despite the limited knowledge on the molecular basis of these processes, the clinical success of mitotic poisons such as taxanes reinforces the interest in these molecules, their involvement in human cancer and the therapeutic opportunities to modulate their function in cancer treatment.
Abbreviations: APC/C, anaphase-promoting complex/cyclosome; CDK, cyclin-dependent kinase; FZR1, fizzy-related 1; PLK1, polo-like kinase 1; SAC, spindle assembly checkpoint
Received November 2, 2006; revised January 11, 2007; accepted January 11, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  O. Gautschi, J. Heighway, P. C. Mack, P. R. Purnell, P. N. Lara Jr., and D. R. Gandara Aurora Kinases as Anticancer Drug Targets Clin. Cancer Res., March 15, 2008; 14(6): 1639 - 1648. [Abstract] [Full Text] [PDF]
|
|